These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 20553285)

  • 21. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
    Andersohn F; Garbe E
    Mov Disord; 2009 Jan; 24(1):129-33. PubMed ID: 19170199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of risk minimization measures for cabergoline-induced cardiac valve fibrosis in clinical practice in Italy.
    Italiano D; Bianchini E; Ilardi M; Cilia R; Pezzoli G; Zanettini R; Vacca L; Stocchi F; Bramanti P; Ciurleo R; Di Lorenzo G; Polimeni G; de Luise C; Ross D; Rijnbeek P; Sturkenboom M; Trifirò G
    J Neural Transm (Vienna); 2015 Jun; 122(6):799-808. PubMed ID: 25230720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low incidence of restrictive valvulopathy in patients with Parkinson's disease on moderate dose of pergolide.
    Růzicka E; Línková H; Penicka M; Ulmanová O; Nováková L; Roth J
    J Neurol; 2007 Nov; 254(11):1575-8. PubMed ID: 17712588
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heart valve disease associated with treatment with ergot-derived dopamine agonists: a clinical and echocardiographic study of patients with Parkinson's disease.
    Rasmussen VG; Poulsen SH; Dupont E; Østergaard K; Safikhany G; Egeblad H
    J Intern Med; 2008 Jan; 263(1):90-8. PubMed ID: 18036161
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
    Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763
    [No Abstract]   [Full Text] [Related]  

  • 27. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.
    Kvernmo T; Härtter S; Burger E
    Clin Ther; 2006 Aug; 28(8):1065-1078. PubMed ID: 16982285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cabergoline in hyperprolactinemia and valvular heart disease].
    Vargas ML; Cervantes CE; Hernando CA; Da Costa CV
    Endocrinol Nutr; 2009 Oct; 56(8):412-7. PubMed ID: 19959151
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non-ergot agonists may also not be spared.
    Chaudhuri KR; Dhawan V; Basu S; Jackson G; Odin P
    Mov Disord; 2004 Dec; 19(12):1522-3. PubMed ID: 15515009
    [No Abstract]   [Full Text] [Related]  

  • 30. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study.
    Junghanns S; Fuhrmann JT; Simonis G; Oelwein C; Koch R; Strasser RH; Reichmann H; Storch A
    Mov Disord; 2007 Jan; 22(2):234-8. PubMed ID: 17094087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heart valve regurgitation, pergolide use, and parkinson disease: an observational study and meta-analysis.
    Corvol JC; Anzouan-Kacou JB; Fauveau E; Bonnet AM; Lebrun-Vignes B; Girault C; Agid Y; Lechat P; Isnard R; Lacomblez L
    Arch Neurol; 2007 Dec; 64(12):1721-6. PubMed ID: 18071034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
    Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
    Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effects of low-dose pergolide therapy on cardiac valves in patients with Parkinson's disease].
    Muraki M; Mikami T; Kitaguchi M; Sugawara T; Isonishi K; Kaneko S; Kashiwaba T; Moriwaka F; Yamada S; Onozuka H; Tsutsui H
    J Cardiol; 2005 Dec; 46(6):221-7. PubMed ID: 16389741
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valvular heart disease in patients with Parkinson's disease treated with pergolide. Course following treatment modifications.
    Dupuy D; Lesbre JP; Gérard P; Andrejak M; Godefroy O
    J Neurol; 2008 Jul; 255(7):1045-8. PubMed ID: 18560792
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk assessment and follow-up of valvular regurgitation in Parkinson patients treated with cabergoline.
    Fietzek UM; Riedl L; Ceballos-Baumann AO
    Parkinsonism Relat Disord; 2012 Jun; 18(5):654-6. PubMed ID: 21908226
    [No Abstract]   [Full Text] [Related]  

  • 36. Pergolide in Parkinson's disease: time for a change?
    Grosset KA; Grosset DG
    Lancet; 2004 Jun; 363(9424):1907-8. PubMed ID: 15183636
    [No Abstract]   [Full Text] [Related]  

  • 37. [Treatment with cabergoline in Parkinson disease can cause heart damage. Continuous treatment requires clinical and echocardiographic check ups].
    Lökk J
    Lakartidningen; 2007 Oct 3-9; 104(40):2892-4. PubMed ID: 17966806
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk of cardiac valve regurgitation with dopamine agonist use in Parkinson's disease and hyperprolactinaemia: a multi-country, nested case-control study.
    Trifirò G; Mokhles MM; Dieleman JP; van Soest EM; Verhamme K; Mazzaglia G; Herings R; de Luise C; Ross D; Brusselle G; Colao A; Haverkamp W; Schade R; van Camp G; Zanettini R; Sturkenboom MC
    Drug Saf; 2012 Feb; 35(2):159-71. PubMed ID: 22204718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabergoline use and risk of fibrosis and insufficiency of cardiac valves. Meta-analysis of observational studies.
    De Vecchis R; Esposito C; Ariano C
    Herz; 2013 Dec; 38(8):868-80. PubMed ID: 23743769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Yamamoto M; Uesugi T; Nakayama T
    Neurology; 2006 Oct; 67(7):1225-9. PubMed ID: 17030757
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.